

Attorney Docket No. Enz-53(C)

RECEIVED  
CENTRAL FAX CENTER

**CLAIM AMENDMENTS**

OCT 15 2007

Claims 1-245 (cancelled)

246. (currently amended) A chemically modified nucleic acid construct, said construct comprising a modified nucleotide, a nucleotide analog, or a combination of the foregoing, wherein said modified nucleotide or nucleotide analog comprises a non-nucleic acid entity, which construct when present in a cell directs is used as a template for the synthesis of a nucleic acid product having biological activity, said product selected from the group consisting of antisense RNA, antisense DNA, sense RNA, ribozymes, messenger RNA, and a combination of any of the foregoing, wherein said non-nucleic acid entity confers nuclease resistance, cell targeting, cellular localization or nuclear localization, or a combination of the foregoing.

247. (previously presented) The construct of claim 246, wherein said construct or a portion thereof is linear, circular or branched.

248. (previously presented) The construct of claim 246, wherein said construct or a portion thereof is single-stranded, double-stranded, partially double-stranded or triple-stranded.

249. (previously presented) The construct of claim 248, wherein said construct is in double-stranded form.

250 (previously presented) The construct of claim 248, having at least one terminus, said terminus comprising a polynucleotide tail.

251. (previously presented) The construct of claim 250, wherein said polynucleotide tail is hybridized to a complementary polynucleotide sequence.

Attorney Docket No. Enz-53(C)

252. (previously presented) The construct of claim 246, wherein said construct comprises DNA, RNA, a DNA-RNA hybrid, a DNA-RNA chimera or a combination of the foregoing.

Claims 253-254 (canceled)

255. (previously presented) The construct of claim 246, wherein at least one of said nucleotide analog or analogs have been modified on the backbone or sidechain or both.

256 (canceled)

257. (previously presented) The construct of claim 246, wherein said non-nucleic acid entity or entities are a natural or synthetic polymer, a natural or synthetic ligand, or a combination thereof.

258. (previously presented) The construct of claim 257, wherein said natural polymer comprises a modified or unmodified member selected from the group consisting of a polypeptide, a protein, a polysaccharide, a fatty acid, and a fatty acid ester, and a combination of the foregoing.

| 259. (currently amended) The construct of claim 246257, wherein said synthetic polymer comprises a homopolymer or heteropolymer.

260. (previously presented) The construct of claim 259, wherein said homopolymer or heteropolymer carries a net negative charge or a net positive charge.

Claims 261-263 (canceled)

Attorney Docket No. Enz-53(C)

264. (previously presented) The construct of claim 257, wherein said ligand or ligands are attached to a single stranded segment, a double stranded segment, a single stranded construct tail, or a sequence complementary to a construct tail, or a combination of the foregoing.

265. (previously presented) The construct of claim 257, wherein said ligand or ligands are macromolecules, small molecules, or a combination of both.

266. (currently amended) The construct of claim 246, wherein said construct carries a net positive charge, or a net negative charge, or is neutral or hydrophobic.

267. (previously presented) The construct of claim 246, wherein said construct comprises unmodified nucleotides and one or more nucleotide analogs.

268. (previously presented) A nucleic acid construct which when present in a cell produces a nucleic acid product, said construct being bound covalently to an entity comprising a ligand in two or more locations on said construct.

269. (previously presented) The construct of claim 268, having at least one terminus, said terminus comprising a polynucleotide tail.

270. (previously presented) The construct of claim 269, wherein said polynucleotide tail is hybridized to a complementary polynucleotide sequence.